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Hepatocellular Carcinoma (HCC) is a leading cause of cancer-related death worldwide. Globally, the most important HCC risk
factors are Hepatitis B Virus (HBV) and/or Hepatitis C Virus (HCV), chronic alcoholism, and dietary exposure to aﬂatoxins. We
have described the epidemiological pattern of 202 HCC samples obtained from Colombian patients. Additionally we investigated
HBV/HCV infections and TP53 mutations in 49 of these HCC cases. HBV biomarkers were detected in 58.1% of the cases; HBV
genotypes F and D were characterized in three of the samples. The HCV biomarker was detected in 37% of the samples while
HBV/HCV coinfection was found in 19.2%. Among TP53 mutations, 10.5% occur at the common aﬂatoxin mutation hotspot,
codon 249. No data regarding chronic alcoholism was available from the cases. In conclusion, in this ﬁrst study of HCC and
biomarkers in a Colombian population, the main HCC risk factor was HBV infection.
1.Introduction
Primary liver cancer is the third leading cause of cancer
death. Moreover, it is the ﬁfth and eighth most frequent
cancer among men and women worldwide, respectively.
The most common histological type of liver cancer is
hepatocellular carcinoma (HCC) accounting for 80 to 90%
of the cases [1].
HCC incidence is highly variable among geographic
regions depending on the prevalence of risk factors and the
incidence of liver cirrhosis; actually, 70 to 90% of HCC
cases develop from cirrhotic liver. Major risk factors of HCC
include Hepatitis B Virus (HBV) and/or Hepatitis C Virus
(HCV) infection and heavy alcohol consumption. In fact,
chronic HBV and HCV infections have been recognized as
liver carcinogens with an imputable fraction of at least 75%2 Hepatitis Research and Treatment
of HCC cases; moreover, it has been estimated that HBV
is responsible for 50 to 80%, whereas HCV is associated to
10 to 25% of HCC cases. Other environmental and genetic
HCC risk factors include dietary exposure to aﬂatoxins, dia-
betes, obesity, nonalcoholic steatohepatitis, and hereditary
hemochromatosis [1–3].
The burden of HCC is growing in diﬀerent continents.
Central and South America were in the past known as low-
incidence liver cancer regions. However, according to the last
published GLOBOCAN analysis, the incidence rates of liver
cancerinthesecountriescorrespondtolowandintermediate
incidence.
Colombia is a country of relatively low incidence of
liver cancer with incidences of primary liver and bile duct
cancers of 3.1/100,000 in males and 2.7/100,000 in females.
However, there is only one active cancer registry in the
country, based in Cali city, an urban area; nevertheless,
whether this situation is representative for the country as a
whole is unknown [4]. Additionally, the national mortality
registry reported around 1,300 deaths from malignant liver
and intrahepatic bile ducts cancer that corresponds to a
mortality rate of 3.23 and 3.09/100000 in men and women,
respectively [5]. So far, there is no study assessing the
geographic variations in incidence or risk factor of chronic
liver disease and liver cancer in Colombia.
Latin American data about HCC risk factors are limited.
The ﬁrst recent prospective study of HCC etiology in 9
LatinAmericancountriesshowedthattheprimaryriskfactor
was chronic HCV infection (30.8%), followed by chronic
alcoholism(20.4%),andchronicHBVinfection(10.8%)[6].
Although HCV infection is the most important HCC risk
factor in Argentina, Mexico, and Brazil, regional diﬀerences
have been described between northern and southern states
in Brazil. Indeed, HBV infection is the most prevalent risk
factor in northern states in Brazil, as in Peru [7–14].
According to the World Health Organization, Colombia
has a moderate endemicity for HBV; although there are sev-
eral epidemiological patterns given the geographic, ethnic,
cultural, and socioeconomic status of the population. Data
from the Colombian National Institute of Health indicate
that, in 2007, a seroprevalence of HBsAg of 0.27% (range
0.08–1.27) was found in 1573 blood bank samples from
across the country. In some rural areas, such as Amazonas
state, rates of chronic HBV carriage over 5% have been
reported [15, 16].
Although the prevalence of HCV infection in the general
population in Colombia is unknown, the WHO estimates a
prevalence between 1 to 2.5% for this country, considering
the data from the National Blood Banks Unit of the
Colombian National Institute of Health. Indeed, while the
seroprevalenceofHCVinblooddonorswas0.7–1%in1993–
1996 and 0.5% in 2002, in a cohort of 500 multitransfused
patients recruited from the two largest cities in Colombia,
Bogota and Medellin, the HCV prevalence was 9% [17].
Data on exposure to aﬂatoxins, a class of mycotoxin
contaminating traditional foodstuﬀ in tropical countries, are
even scarcer [18]. A survey of aﬂatoxin contamination in
selected Colombian foods was conducted over a 12-month
period on a total of 248 samples collected in supermarkets,
retail stores, and stock centres [19]. Aﬂatoxins were detected
in 22 samples, including 14 of 109 samples of corn and corn
products and 4 of 40 samples of rice and rice products.
Twelve of the 22 positive samples exceeded the maximum
tolerable level of AFB1 adopted by most countries (5ng/g),
including 10 samples of corn and corn products. Given that
corn is part of the common diet of Colombian inhabitants;
it is likely that AFB1 may represent a signiﬁcant exposure
at least in a fraction of the population. Finally, the role
of chronic alcoholism (mostly in the form of cane sugar
alcohol) may also be signiﬁcant [20–23].
In the present study, we describe the sociodemographic
variables of 202 HCC cases, who attended four reference
institutions in Colombia during the period 2000–2007, and,
for the ﬁrst time, the prevalence of biomarkers in a series
of 49 HCC cases. We report that the HBV biomarker was
detectable in 58.1% of the cases and the HCV biomarker in
37%. Among TP53 mutations, 10.5% occur at the common
aﬂatoxin mutation hotspot, codon 249, although G12457T
(exon 5) and G13804A (exon 8) were present in 2.9% of
theHCCsamples.Unfortunately,dataonchronicalcoholism
was not available from the cases. These results suggest that
the principle HCC risk factor in this Colombian population
is HBV infection and low to moderate of AFB1 exposure.
2.MaterialsandMethods
2.1. Liver Samples. HCC samples were obtained from
archived cases in the Departments of Pathology of four
institutions in the three largest cities in Colombia, Bogota,
Medellin, and Cali, during the period from 2000 to 2007.
TheinstitutionscorrespondtoFundacionSantaFedeBogota
(47 cases), Hospital Pablo Tobon Uribe (31 cases), Facultad
de Medicina, Universidad de Antioquia (114 cases), and
Hospital Universitario del Valle (10 cases).
From 202 HCC cases registered at the archives, 49
paraﬃn-ﬁxed liver samples were available for immuno-
chemistry and molecular biology assays. The histological
pattern and grade of tumor diﬀerentiation (Edmonson and
Steiner grading system) was assigned by two independent
pathologists.
2.2. Immunochemistry Analysis
2.2.1. p53. The isoforms of p53 were detected on deparaf-
ﬁnized tissue sections using standard protocols with CM1
antibody (rabbit polyclonal immunoglobulin G antihu-
man p53, 1/500, Novacastra Laboratories Ltd., Newcas-
tle, UK). The antibodies were detected using biotiny-
lated immunoglobulin G, streptavidine-peroxidase, and
diaminobenzidine-based detection (Vector Laboratories,
Inc., Burlingame, Calif, USA).
2.2.2. HBx and Core HCV. After deparaﬃnization and
rehydratation antigen retrieval was applied by vaporizer
in Target Retrieval Solution pH 6.0 (Dako). As primary
antibody Core HCV monoclonal antibody (anti-Core HCVHepatitis Research and Treatment 3
aa70–90 CHEMICON, Millipore) or HBx monoclonal anti-
body Hepatitis B Virus X-Protein (Trans-Activator X Gene
Product) monoclonal antibody (Clon 227, CHEMICON,
International, Inc.) were used at a dilution 1:50. The kit
ultravision LP detection System HRP Polymer and DAB
Plus Chromogen (Lab Vision corporation) was used for the
detection of HBV and HCV antigens.
2.2.3. AFB1-DNA Adducts. The standardization of adducts
detection was performed using liver tissue sections from
rats treated with AFB1. The liver tissue sections were
labeled using the antibody highly speciﬁc for AFB1-Fapy
adducts 6A10, developed and characterized by Hsieh et
al. [24]. Brieﬂy, the sections were ﬁrst treated with 5mM
Na2CO3/30mM NaHCO3 (pH 9.0) to open the guanine
adducts ring. The antigen retrieval was performed using
citrate buﬀer pH 6.0 (Dako). The liver sections were then
t r e a t e dw i t hR N a s eA( 1 0 0 µL/mL, Fermentas, RNase A,
DNase, and Protease-free), with Proteinase K for 10min at
37◦C( 1 0µL/mL, Gentra Puregene) and with NaOH 50mM
in 40% ethanol for DNA denaturation. Slides were then
incubated with the antibody 6A10 at a dilution 1:20 at 4◦C
overnight.Thereactionwasdetectedusingthekitultravision
LP detection System HRP Polymer & DAB Plus Chromogen
(Lab Vision Corporation).
2.2.4. DNA Extraction. DNA was extracted from 4µm
unstained paraﬃn sections. The sections were deparaﬃned
inxyleneandethanol.Then,thetumortissueareasofinterest
were scrapped into 1.5mL sterile microcentrifuge. DNA was
extracted using QIAmp DNA Micro kit (Qiagen, Hilden,
Germany), according to the manufacturer’s instructions.
D N Ae x t r a c t sw e r es t o r e da t−20◦C.
2.2.5. TP53 Mutations. DNA was used for ampliﬁcation of
exon 7 of TP53 gene with the primers ﬂanking the exon
(sense-333 ACTTGCCACAGGTCTCCCCAA and antisense-
313 AGGGGTCAGCGGCAAGCAGA) as described else-
where [25]. Brieﬂy, the PCR was carried out in a volume
of 25µL containing 5µLo fD N A ,1 Uo fP l a t i n u mTaq
DNA polymerase High Fidelity (Invitrogen Carlsbad, USA),
0.4µMo fe a c hp r i m e r ,d N T P( 2 0 0 µM each), 1X High
Fidelity Buﬀer Taq polymerase (Invitrogen), 0.5mM of
MgSO4 (Invitrogen), and nucleases-free water (Amresco,
Solon, USA). The PCR reaction involved a 15min Hot-Star
Taq polymerase activation at 95◦C followed by 45 cycles of
denaturing at 94◦C for 30sec, annealing at 60◦C for 30sec
andextensionat72◦Cfor30sec,followedbyaﬁnalextension
for 10min at 72◦C.
The speciﬁc G to T transversion at codon 249 of exon 7
was analyzed by Restriction Fragment Length Polymorphism
(RFLP). PCR products were digested by HaeIII restriction
endonuclease (Promega, Madison, USA). The fragments
were visualized on 3% agarose gel stained with ethidium
bromide, eluted, reampliﬁed, and sequenced by automated
sequencing (sequencer 3730xl). Additionally, all samples
were analyzed by direct sequencing of PCR products cor-
responding to TP53 exons 7 and also exons 5, 6, and 8 as
described elsewhere [26]. All results represent a minimum of
two fully independent analyses.
2.2.6. Detection of HBV. HBx DNA sequences were ampli-
ﬁed by PCR. Brieﬂy, the PCR was carried out in a
20µL volume containing Colorless GoTaq ﬂexi buﬀer,
MgCl2 1.5mM, dNTP (200µM each), primers DG-XF4
(GGGACGTCCTTTGTCTACGT), and DG-X1R (GGGA-
GACCGCGTAAAGAGAG) and 0.8U of GoTaq DNA poly-
merase (Promega). The PCR reaction involved a step at 95◦C
f o r2 m i nf o l l o w e db y5 0c y c l e so fd e n a t u r i n ga t9 4 ◦Cf o r
45sec, annealing at 62◦C for 45sec and extension at 72◦Cf o r
45sec, followed by a ﬁnal extension for 7min at 72◦C. PCR
products were analyzed by electrophoresis on 2% Agarose
gels and ethidium bromide staining.
2.2.7. HBV Genotyping. T h es m a l lSg e n ef r a g m e n to fH B V
was ampliﬁed using YS1-YS2 in the ﬁrst round, and s3-
s3as (319nt) in a second round [27, 28], or hep3–hep33 as
a unique round of PCR [29]. All sequences obtained were
compared with GenBank available sequences. Phylogenetic
analyses by Neighbour Joining and Maximum Likelihood
were conducted with MEGA 5.1; this program was also used
for tree representation.
3. Results
3.1. Characteristic of Study Population. During the period
2000–2007, 192 HCC cases were diagnosed at Fundacion
Santa Fe de Bogota (23.3%), Hospital Pablo Tobon Uribe
(15.3%) and Facultad de Medicina, Universidad de Antio-
quia (56.4%). Additionally, 10 cases (5%) were diagnosed
at Hospital Universitario del Valle during the period 2000–
2004.
Among the total HCC cases, 36% were diagnosed in
females and 64% in males corresponding to a male/female
ratio of 1.8:1. The average age was 62 years, the median was
61 years, and the age range was 22 to 90. The records of
HCC by age showed a higher frequency starting in the sixth
decade of life in both populations genders. No data from
the cases were available on HCV or HBV status or alcohol
consumption.
The 49 HCC cases included in this study were classiﬁed
according to the Edmonson-Steiner criteria as G1 well-
diﬀerentiated (4.9%), G2 moderately diﬀerentiated (39%),
or G3 poorly diﬀerentiated (56.1%). The trabecular type was
the most frequent (56.5%) followed by solid (21.7%), mixte
(13%), glandular (4.4%), and pseudoglandular (4.4%). The
clinicopathological characteristics of the HCC cases included
in this study are summarized in Table 1.
3.2. Mutations in TP53 Gene. The 249ser mutation was inves-
tigatedinHCCsamplesbyRFLPfollowedbysequencingand
bydirectsequenceofTP53exon7(Figure 1).Thepresenceof
a mutation was conﬁrmed by both techniques in 4 (10.5%)
of 38 HCC samples. The mutation was associated with
overexpression of p53 in two of these samples (10%–50% of
cells stained); for the other two cases, the immunochemistry4 Hepatitis Research and Treatment
Table 1: Clinicopathological data of HCC cases diagnosed at
four health reference institutions during the period 2000–2007 in
Colombia.
Frequency (%)n = 49
Mean age 63.5 years
Age range 25–88 years
Gender female/male 43.2%/56.8%
Edmondson and Steiner’s grade
G1 4.9%
G2 39%
G3 56.1%
Histological type
Trabecular 56.5%
Solid 21.7%
Mixte 13%
Glandular 4.4%
Pseudo-glandular 4.4%
Biomarkers
HBV 58.1% (25/43)
HCV 37% (10/27)
Coinfection 19.2% (5/26)
AFB1-DNA adducts 0% (0/31)
TP53 gene
Exon 7 (249ser mutation) 10.5% (4/38)
Exon 5 (G12457T mutation) 2.9% (1/34)
Exon 8 (G13804A mutation) 2.9% (1/34)
analysis was not available. No additional mutations were
detected in any other position of TP53 exon 7.
The analysis by direct sequence of TP53 exons 5, 6, and 8
revealed two point mutations in exon 5 (G12457T/V157F)
and exon 8 (G13804A/C275Y) and one SNP in exon 6
(A12708G/R213R) in three (8%) HCC samples of the 34
without 249ser mutation. No accumulation of p53 protein
was demonstrated in the HCC sample exhibiting the muta-
tion G12457T. The assay of p53 protein by immunochem-
istry was not available for the other two samples.
3.3. AFB1-DNA Adducts. A total of 31 liver tissue samples
were analyzed for AFB1-DNA adducts by immunohisto-
chemistry. This biomarker was detected in hepatocyte nuclei
of treated rat liver tissue included in each of the assays
as a positive control; however, none of the HCC samples
analyzed was positive for DNA adducts (Figures 2(a) and
2(b)). Twenty-three HCC samples were analyzed for both
AFB1-DNA adducts and TP53 exon 7, but none of these
samples was positive for the 249ser mutation.
3.4. HBV Infection Biomarkers. Considering that data on
the HBV infection status of the HCC cases analyzed was
unavailable, two biomarkers were included in order to
identify the cases associated with HBV infection. Twenty-
ﬁve HCC samples (58.1%, 25/43) were positives for nuclear
HBx protein by immunohistochemical detection (Figures
2(c) and 2(d)) and/or HBx sequence detection by PCR
(nucleotides 1411–1549). From the 25 positives HCC cases,
5 samples were positive for both biomarkers; eleven samples
werepositives foroneofHBVbiomarkers(HBximmunohis-
tochemical detection or HBx PCR), while 9 samples positive
were analyzed for only one of the biomarkers.
The 249ser and G13804A (exon 8) mutations were
identiﬁed in two samples positive for HBV biomarkers.
Regrettably,theanalysisofHBVbiomarkerswasnotavailable
in one of the samples positive for the 249ser mutation.
3.5.HBVGenotypes. ThesmallSgenefragmentwasanalyzed
by PCR and sequenced in 23 HCC samples positive for HBV
biomarkers (HBx protein and/or HBx PCR). However, it
was successfully sequenced in just three samples. One of the
reasons for this limited number of samples characterized for
the viral genotype could be the quality of the DNA extracted
from the paraﬃn-ﬁxed liver tissues.
Phylogenetic study of the S sequence showed that two
isolates belonged to genotype F and one isolate to genotype
D according to the grouping with HBV prototype GenBank
sequences. Similar topology was observed between trees
generated by the diﬀerent inference methods (data not
shown). The identiﬁcation of the subtype was not available
in these samples taking into account the limitations of the
size sequence (Figure 3).
3.6. HCV Infection Biomarker. T h eC o r eH C Vp r o t e i nw a s
detected by immunohistochemistry in 37% of the samples
analyzed (10/27); cytoplasmic staining was observed in all
positive HCC samples (Figures 2(e) and 2(f)). HBV/HCV
coinfectionwasdemonstratedin19.2%(5/26)ofthelivertis-
suesamplesincludedintheassays;twowerepositiveforboth
biomarkersofHBVandHCVinfection,whiletheotherthree
were positive for HBx by immunohistochemical detection or
HBx PCR, in addition to the Core HCV protein detection.
4. Discussion
This is the ﬁrst study of HCC biomarkers carried out in
a Colombian population. The health centers of this study
included two leading Departments of Pathology at the
national level (Fundacion Santa Fe de Bogota and Facultad
de Medicina, Universidad de Antioquia) and two of the most
important hospitals in Medellin and Cali Cities (Hospital
Pablo Tobon Uribe and Hospital Universitario del Valle).
Although, the 202 cases recruited in these centers
during the period 2000–2007 do not represent the national
registries, the data obtained from these reference institutions
contributes to the knowledge of HCC epidemiology of
Colombia.
The burden of HCC has demonstrated an increasing
trend over the past two decades in some regions of the
world [1]. Even in Latin America, previously considered
as a low incidence of liver cancer region, the data from
diﬀerent countries revealed increasing rates of HCC. Indeed,
the mortality rates for primary liver cancer have increased in
Mexico from 4.1/100.000 inhabitants in 2000 to 4.7/100.000
in2006[30].AsimilartendencyisobservedinColombia;theHepatitis Research and Treatment 5
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Figure 1: TP53 249ser mutation in HCC cases from Colombia. (a) TP53 mutation at codon 249 was identiﬁed by restriction digestion.
Presence of an undigested 158bp fragment is indicative of mutation. Wild-type pattern: Lanes 2 (negative control: DNA from healthy donor
lymphocytes),4to8,11,and13(HCCcases).Mutantpattern:Lanes3(positivecontrol:DNAfromPLC/PRF/5cellline),9,10,and12(HCC
cases). MW: molecular weight marker 100bp. (b) Sequencing chromatograms of a mutant HCC case (a), showing the change from AGG to
AGT and a wild-type HCC case (b).
mortality rates for primary liver and intrahepatic bile duct
cancer were 4.8/100.000 inhabitants in 2000 and 5.0/100.000
inhabitants in 2001 [5, 31]. Moreover, the mortality rates for
these cancers in Antioquia state increased from 6.9/100.000
in 2003 to 33/100.000 in 2005 [32]. The increased trend in
mortality rates for the country and for Antioquia state could
be related to improved diagnostic procedures in the health
system. On the other hand, changes in risk factors over time
could also be implicated.
The analysis of GLOBOCAN data revealed an overall
male:female ratio of 2.4:1. The reported ratios usually
varied between 2:1 to 4:1 depending on the incidence rates
and risk factor patterns over the world. The higher rates of
liver cancer in male population could be due to diﬀerences in
risk factor exposure [33].
Central and South America have the lowest reported
male:female ratio for liver cancer; for example, 1.2:1
in Colombia and 1.6:1 in Costa Rica [33]. However, as
mentioned previously the data sources from Colombia in the
GLOBOCAN database are restricted to the cancer registry of
Cali city. In this study, from the 202 HCC cases, diagnosed
at 4 institutions in Bogota, Medellin, and Cali cities, the
male:female incidence ratio was 1.8:1.
In low-risk populations, the highest age-speciﬁc rates
arise in patients around 75 years old while in high-risk
population it occurs around 60 to 65 years old. The age-
speciﬁc pattern is related to diﬀerences in HBV and HCV
prevalence, age of infection, and other relevant risk factors
in a population [33]. The mean age of the 202 HCC cases
of this study was 62 years and the median 61 years. These
data are similar to the median age in other studies carried
out in Peru [34] and Argentina [13] and also in a multicenter
prospective HCC study in 9 Latin American countries [6].
Nevertheless, in other studies the mean age of HCC patients
was 41.4 years in the Peruvian population [35], 55.9 years in
the Brazilian population [12], and 56 years in the Chilean
population [14]. The mean age diﬀerence among the HCC
studies in Latin American countries could be related to the
risk factor patterns in each country.
According to the IARC TP53 database [36] (R15,
http://www-p53.iarc.fr), TP53 mutations have been
described in up to 31.4% of HCC cases, with the 249ser
mutation being the most common. This mutation has been
associated with AFB1 exposition and there is robust evidence
that supports this ﬁnding. AFB1 is classiﬁed as an IARC
Group 1 carcinogen for the liver and causes an inactivating
mutation at codon 249 of the TP53 tumor suppressor gene,
inducing the substitution of an arginine by a serine (R249S
mutation) [1].
This mutation has a high frequency in populations
from the highest-HCC-incidence areas like Qidong, China
(43.8%) [37], Guangxi, China (36%) [38], and Gambia
(39.8%) [39]. Moreover, 71.5% of reported mutations in
codon 249 of TP53, which correspond to the transversion6 Hepatitis Research and Treatment
(a) (b)
(c) (d)
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Figure 2: Immunohistochemical detection of HCC biomarkers. (a) Liver tissue specimens from Sprague-Dawley rats treated with
1.25mg/Kg of AFB. (b) Liver sample from patient with HCC without apparent exposure to AFB. (c) HCC case with detection of HBx
protein, high expression, and nuclear localization. (d) Negative HCC case to HBx protein detection. (e) HCC case with detection of HCV
Core protein, high expression in the cytoplasm of liver cells. (f) HCC case without expression of HCV core protein. Original magniﬁcation
×400.
G:C → T : Ah a v eb e e nd e t e c t e di nH C C[ 36], whereby
this mutation could be a biomarker for dietary exposure to
anatoxin.
In this study, the 249ser mutation was detected in 10.5%
(4/38) of the HCC samples. A similar prevalence was
reported in other areas in Anhui, Province of China (10.5%)
[40], India (9.5%) [41], and Taiwan (13%) [42]; in recent
studies a prevalence around 2% was reported in Turkey [43]
a n di nT a i w a n[ 44]. The main risk factor of HCC in these
studies was HBV infection, similar to that reported in this
Colombian population.
The249ser mutationfrequencydescribedfortheﬁrsttime
in a Colombian population suggests an AFB1 exposure level
between low to intermediate. Three of the four HCC samplesHepatitis Research and Treatment 7
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Figure 3: Phylogenetic tree of HBV genotypes generated by
Neighbour joining method (MEGA), using HBV S gene sequences.
The accesion number followed by genotype indentity is indicated.
Bootstrap values are shown (1000 repetitions). HKY was used to
access distances. Red arrows show the Colombian strain position.
positive for this mutation were cases recruited in one of the
most important reference national health center (Fundacion
Santa fe de Bogota); probably these samples corresponded to
HCC cases from rural areas.
A correlation between AFB1 adducts and the 249ser was
demonstrated in two studies carried out in Taiwan [42, 44].
However, none of the HCC cases included in our study
were positive for AFB1-DNA adducts, even though there is
evidence of AB1 contamination in corn and rice collected
in supermarkets, retail stores, and stock centers in Colombia
[19].
Untilnow,thereareonlytwostudiespublishedregarding
the 249ser mutations in HCC cases in Latin American
countries. One of them was carried out in Mexico in 16 HCC
samples with a 249ser frequency of 19% [45]. The other one
was carried out in Brazil, where the maximum AFB1 level in
food allowed is higher than in North America and Europe;
the 249ser prevalence was 28% (21/74) by PCR-RFLP and
16% by direct sequencing [46]. The 249ser prevalence data of
16% in Brazil and 10.5% in Colombia using both techniques
(RFLP and direct sequence) for mutation analysis suggest
that dietary exposure to AFB1 is an HCC risk factor in these
Latin America countries, although not as important as in
Africa and Asia.
Diﬀerent studies have suggested that 249ser mutation
occurs almost exclusively in the context of chronic HBV
infection in addition to AFB1 chronic dietary exposure [1].
Kirk et al. demonstrated in a prospective study in Gambia,
a multiplicative eﬀect on HCC risk resulting from HBV
chronic infection and the mutational eﬀect of AFB1 on the
TP53 gene (codon 249). Actually, in 216 HCC incident cases
and 121 cirrhosis cases, the risk for HCC was associated
with HBV markers with an odds ratio (OR) of 10.0 (95%,
CI: 5.16–19.6), 249ser with an OR of 13.2 (95%, CI: 4.99–
35.0), and both markers with an OR of 300 (95%, CI: 48.6–
3270) [39]. In this study of a Colombian population, the
analysis of HBV biomarkers and TP53 exon 7 sequences
was performed in 32 HCC samples, including 3 from 4
249ser mutation-positive samples. One of three samples was
positive for both biomarkers (HBV and 249ser). The negative
resultsforHBVbiomarkersintheothertwosamplescouldbe
explained by technical limitations of immunohistochemistry
and PCR protocols used in this study. However, Kirk et
al. have described 15.3% of HCC samples HBV(−)/TP53
249ser(+) [39]. Additionally, we report two point mutations,
G12457T (exon 5) and G13804A (exon 8), located in the p53
DNA-binding domain. These missense mutations modify
the stability and transactivating properties of p53 protein;
according to the TP53 database, their frequency in HCC
is 2.1 and 0.26%, respectively [36]. In this study, the
mutations were described in two HCC cases (2.9%, 1/34,
each one).
HBV biomarkers were demonstrated in 58.1% of the
HCC samples analyzed in this study by HBx protein
immunohistochemistry detection and HBx PCR. These data
areexpectedconsideringtheepidemiologicalpatternofHBV
infectioninColombia,averagemoderateprevalencebutwith
regions of high prevalence [47, 48]. A higher frequency of
HBVinfectionthanotherriskfactorshasalsobeendescribed
in HCC patients from Peru (38.9%, 42.2%) [34, 35] and in
states of the north eastern and northern regions of Brazil
(average 43.1%), including Para (71.4%, 5/7), Bahia (45%,
9/20), Minas Gerais (37.8%, 14/37), and Espirito Santo
(41.6%, 10/24) [12]. HBV infection was diagnosed in these
studies by the detection of HBsAg in serum samples from
the patients. As mentioned previously, data on HBsAg in
the Colombian patients were not available from the clinical
records.
The phylogenetic study of the S sequence in three HCC
samples in this study was successful. Two isolates were
characterized as genotype F and one as genotype D. The
HBV genotypes in the Colombian population have been
characterized in four studies in blood donor populations,
pregnant women, and recently in end-stage liver diseases
cases. The predominance of genotype F was demonstrated
in three of these studies (77%, 87.23%, and 100%) [49–51].8 Hepatitis Research and Treatment
Additionally,genotypesA,D,C,G,andEwerealsodescribed
in some cases of those studies [49, 50, 52].
The HCV infection status was established by HCV
Core protein immunohistochemistry detection. Regrettably,
molecular biology markers for HCV infection were not
available. A prevalence of 37% was found in the HCC sam-
ples analyzed in this study with an HBV/HCV coinfection
prevalence of 19.2%. In other Latin American countries
where the HBV infection is the most important HCC
risk factor, the prevalence of the HCV marker is lower
(5.3%–16.6%)thandescribedinthisColombianpopulation.
Nevertheless,theHCVbiomarkerinthesestudiescarriedout
in Peru [34, 35] and Brazil [12] corresponded to anti-HCV
detection; unfortunately, data on this biomarker were not
available for the Colombian population in this study.
On the other hand, HCV infection is the predominant
HCC risk factor in Argentina, Chile, and the South eastern
states of Brazil (Rio de Janeiro, Sao Paulo, Parana, and
Rio Grande do Sul). The prevalence range of the serum
anti-HCV marker was 32.8% to 44% in HCC cases from
these South American countries [12–14]. Furthermore,
in a recent prospective multicenter study of HCC cases
from 9 Latin American countries, including Argentina,
Brazil, Chile, Colombia, Uruguay, and Venezuela, the main
HCC risk factor was HCV infection (30.8%), followed
by alcohol (20.4%), HBV infection (10.8%), and HCV
plus alcohol (5.8%) [6]. Some cases from this multicenter
study corresponded to patients recruited in a prospective
study carried out at Hospital Pablo Tobon Uribe (HPTU)
in Medellin city; Interestingly, from the total 131 cases
of end-stage liver disease in this hospital in the period
of the study, the most important risk factor was chronic
alcoholism (37.4%, 49/131), whereas viral infection ranked
second (10.7% HBV and 6.9% HCV); the serum markers
for diagnosis of viral infections were HBsAg and anti-
HCV [51]. Chronic alcoholism was also an important risk
factor in HCC patients in Argentina (42%), Brazil (37%),
and Chile (31%) [12–14]. These results suggest that the
HCC risk factors pattern in Latin America is changing to
the pattern seen in developed countries, where one of the
principle HCC risk factors is chronic alcohol abuse [1].
However, further investigations are necessary to conﬁrm this
hypothesis.
Unfortunately, only demographic and histopathological
data but not alcohol intake were available from the HCC
cases in this study. The discrepancy between the risk factor
pattern revealed in this retrospective study carried out in
four Departments of Pathology from health institutions in
Cali, Medellin, and Bogota cities and in the prospective
one performed at hepatology unit of HPTU in Medellin
city could be partially explained by diﬀerences in age
range, male:female ratio, viral infection biomarkers, and
quality of clinical information, including follow-up of the
patients in the second study. However, the predominance of
HBV infection compared to HCV infection was described
in both populations. Further case-control studies in the
Colombian population are necessary in order to deﬁne the
burden of alcohol intake and viral infections as HCC risk
factors.
In conclusion, this ﬁrst retrospective study exploring
the epidemiological features of HCC in patients from 4
leading health institutions in the three most important cities
in Colombia revealed that the majority of the patients are
male and in their 6th to 7th decade of life. The main HCC
risk factor is HBV infection but the presence of codon 249
mutations, a biomarker of AFB1 exposure, was also found in
some HCC samples.
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